Biostage, Inc. (BSTG) Financial Statements (2023 and Earlier)
Company Profile
| Business Address |
84 OCTOBER HILL ROAD HOLLISTON, MA 01746 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 1,242 | 1,026 | 913 | 1,305 | 4,038 | 2,941 | 7,456 | ||
| Cash and cash equivalents | 1,242 | 1,026 | 913 | 1,305 | 4,038 | 2,941 | 7,456 | ||
| Restricted cash and investments | 50 | 50 | 50 | 50 | |||||
| Receivables | 300 | 42 | 21 | ||||||
| Inventory, net of allowances, customer advances and progress billings | 75 | ||||||||
| Inventory | 75 | ||||||||
| Prepaid expense | 58 | 403 | 284 | 347 | 289 | 291 | |||
| Other current assets | 12 | 24 | 15 | 90 | 86 | 212 | |||
| Other undisclosed current assets | 225 | 174 | 145 | 362 | (300) | 330 | |||
| Total current assets: | 1,587 | 1,677 | 1,407 | 2,154 | 4,413 | 3,486 | 7,882 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 169 | 182 | 191 | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 110 | 217 | 394 | 479 | 632 | 1,065 | 1,074 | ||
| Total noncurrent assets: | 279 | 399 | 585 | 479 | 632 | 1,065 | 1,074 | ||
| TOTAL ASSETS: | 1,866 | 2,076 | 1,992 | 2,633 | 5,045 | 4,551 | 8,956 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 798 | 317 | 438 | 404 | 923 | 962 | 357 | ||
| Accounts payable | 676 | 31 | 160 | 923 | 962 | 357 | |||
| Accrued liabilities | 178 | 118 | 110 | ||||||
| Employee-related liabilities | 11 | 39 | 177 | ||||||
| Other undisclosed accounts payable and accrued liabilities | 111 | 69 | 143 | 134 | |||||
| Debt | 284 | 102 | |||||||
| Derivative instruments and hedges, liabilities | 2 | 17 | 33 | 98 | 16 | 605 | |||
| Due to related parties | 300 | ||||||||
| Other undisclosed current liabilities | 4,036 | 138 | 241 | 160 | 383 | 1,210 | 297 | ||
| Total current liabilities: | 4,836 | 756 | 814 | 662 | 1,622 | 2,777 | 654 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 59 | 195 | 89 | ||||||
| Long-term debt, excluding current maturities | 120 | ||||||||
| Operating lease, liability | 59 | 75 | 89 | ✕ | ✕ | ✕ | ✕ | ||
| Other undisclosed noncurrent liabilities | (59) | (75) | |||||||
| Total noncurrent liabilities: | 59 | 195 | 89 | ||||||
| Total liabilities: | 4,895 | 951 | 903 | 662 | 1,622 | 2,777 | 654 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | (3,029) | 1,125 | 1,089 | 1,971 | 3,423 | 1,774 | 8,302 | ||
| Common stock | 108 | 94 | 82 | 57 | 25 | 171 | 141 | ||
| Additional paid in capital | 73,801 | 69,991 | 65,102 | 57,677 | 50,157 | 37,921 | 32,908 | ||
| Accumulated other comprehensive loss | (8) | ||||||||
| Accumulated deficit | (76,938) | (68,960) | (64,095) | (55,763) | (48,234) | (36,318) | (24,739) | ||
| Other undisclosed stockholders' equity attributable to parent | 1,475 | ||||||||
| Total stockholders' equity: | (3,029) | 1,125 | 1,089 | 1,971 | 3,423 | 1,774 | 8,302 | ||
| TOTAL LIABILITIES AND EQUITY: | 1,866 | 2,076 | 1,992 | 2,633 | 5,045 | 4,551 | 8,956 | ||
Income Statement (P&L) ($ in thousands)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 82 | 118 | ||||||
| Cost of revenue | (116) | (139) | ||||||
| Gross profit: | (34) | (21) | ||||||
| Operating expenses | (8,636) | (5,325) | (8,870) | (7,841) | (11,468) | (12,092) | (11,680) | |
| Operating loss: | (8,636) | (5,325) | (8,870) | (7,841) | (11,468) | (12,126) | (11,701) | |
| Nonoperating income (expense) | 658 | 460 | 538 | 312 | (448) | 547 | (3) | |
| Other nonoperating income (expense) | 70 | (3) | (7) | (111) | 547 | |||
| Interest and debt expense | 408 | (129) | ||||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 129 | |||||||
| Loss before gain (loss) on sale of properties: | (7,570) | (4,865) | (8,332) | (7,529) | (11,916) | (11,579) | (11,704) | |
| Other undisclosed net loss | (408) | |||||||
| Net loss available to common stockholders, diluted: | (7,978) | (4,865) | (8,332) | (7,529) | (11,916) | (11,579) | (11,704) | |
Comprehensive Income ($ in thousands)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (7,978) | (4,865) | (8,332) | (7,529) | (11,916) | (11,579) | (11,704) | |
| Other comprehensive income (loss) | 8 | (9) | ||||||
| Comprehensive loss, net of tax, attributable to parent: | (7,978) | (4,865) | (8,332) | (7,529) | (11,916) | (11,571) | (11,713) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.